Suppr超能文献

普萘洛尔及新型抗高血压药物在高血压治疗中的应用

Propranolol and newer antihypertensive drugs in the management of hypertension.

作者信息

Moser M

出版信息

Adv Cardiol. 1979;26:38-43. doi: 10.1159/000402387.

Abstract

Among the newer antihypertensive agents are the beta-blocking drugs, such as propranolol. These agents are useful as second-step drugs to be used if diuretic therapy alone is not effective. In mild to moderately severe hypertension, propranolol, in does of up to 480 mg/day in combination with a thiazide diuretic, has been found to be effective in over 80% of patients on long-term therapy. This degree of response is essentially similar to that noted with a combination of reserpine and a diuretic agent. Although some observers believe that propranolol produces many fewer side effects than the other step 2 drugs (reserpine and alpha-methyldopa), there are some patients who do experience restlessness, insomnia, and depression. Clonidine may be substituted for another step 2 drug, is of moderate potency, but may not be tolerated by a large number of patients because of the severe dry mouth and drowsiness that it produces. Prazosin appears to be a suitable substitute for hydralazine as an effective vasodialator if thiazides plus propranolol or thiazides plus reserpine or alpha-methyldopa are not effective. In some instances, it many be an acceptable second-step drug because of its alpha-adrenoreceptor-blocking properties. The angiotensin II competitive inhibitors or converting enzyme inhibitors may in the future have some place in the management of hypertension.

摘要

较新的抗高血压药物中有β受体阻滞剂,如普萘洛尔。如果单独使用利尿剂治疗无效,这些药物可作为第二步用药。在轻度至中度严重高血压患者中,已发现普萘洛尔每日剂量高达480毫克与噻嗪类利尿剂联合使用,对超过80%的长期治疗患者有效。这种反应程度与利血平和利尿剂联合使用时的情况基本相似。尽管一些观察家认为普萘洛尔产生的副作用比其他第二步药物(利血平和α-甲基多巴)少得多,但仍有一些患者会出现烦躁、失眠和抑郁。可乐定可替代另一种第二步药物,其效力中等,但由于会产生严重的口干和嗜睡,可能无法被大量患者耐受。如果噻嗪类药物加普萘洛尔或噻嗪类药物加利血平或α-甲基多巴无效,哌唑嗪似乎是一种合适的替代肼屈嗪的有效血管扩张剂。在某些情况下,由于其α-肾上腺素受体阻断特性,它可能是一种可接受的第二步药物。血管紧张素II竞争性抑制剂或转化酶抑制剂未来可能在高血压治疗中占有一席之地。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验